CCL2 and neoplasm: For instance, Carlumab, an MCP-1 specific monoclonal antibody, can directly against the binding of MCP-1 to its receptor, inhibiting downstream signaling activation and overcoming MCP-1 promoted tumor progression (Brana et al., 2015).